Clinical Trial

Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder, with characteristics of defecation related abdominal pain and diarrhea. Routine treatment strategy for IBS-D is symptom-based with unsatisfactory results, while there is a growing interest in complementary and alternative medicine such as Traditional Chinese Medicine. However, lack of high-quality evidences being the obstacle for its development. This study aims to evaluate the efficacy of Fengliao Changweikang Keli (FLCWK) on symptoms and health-related quality of life in mild to moderate IBS-D patients. After 2-week run-in period, each participant will be randomized to a sequence of six 4-week double-blind treatment periods of FLCWK 8 g three times daily or placebo, separated by 2-week washout periods.
Trial Details
NCT Number NCT07061184
Lead Sponsor Peking Union Medical College Hospital
Conditions Irritable Bowel Syndrome - Diarrhoea, Traditional Chinese Medicine (TCM), N of 1 Study Design, Efficacy and Safety
Enrollment 50 participants
Start Date 2025-11
Primary Completion 2027-11 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-07-11